Project Grant DP2DK143366
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$1.4M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program, valued at $138,489, supports research to develop a novel "methyl arginine targeting chimera" for the lysosomal degradation of intracellular proteins. The project aims to characterize the mechanisms for applying this degradation route synthetically (Aim 1) and identify endogenous substrates of this degradation pathway (Aim 2). This research holds the potential to offer an...
This $1,088,500 Project Grant was awarded on September 20, 2024 by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant supports research to enhance the cancer-killing abilities of engineered macrophage (CAR-M) cellular immunotherapies, with the goal of overcoming limitations of current chimeric antigen receptor T-cell (CAR-T) therapies. The project, conducted by the University of California, Santa Barbara, aims to...
This Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University aims to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The 5-year project will: Determine the detailed molecular mechanisms, including target receptors and downstream signaling pathways, that two identified microproteins use to modulate macrophage polarization. Screen a large,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...
The National Institute of General Medical Sciences (NIGMS) awarded a $379,131 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of North Carolina at Chapel Hill. The goal of this 5-year grant, effective September 1, 2024, is to develop rapid characterization strategies and predictive algorithms to guide the design of macromolecule-based therapeutics, particularly for disrupting protein-protein interactions. The research will focus on how...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $550,255 in funding to The Regents of the University of California, San Francisco (UCSF) to develop and apply a new "structural surfaceomics" technology. This technology aims to systematically identify tumor-specific protein conformations on cell surfaces that could serve as novel immunotherapy targets, with an initial focus on acute myeloid leukemia (AML). The key...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) totaling $373,375 will support research to understand the interactions between ultra-small nanoparticles (USNPs) and inflammatory monocytes, and how these interactions can be leveraged to target inflammation. The research aims to: 1) determine the fundamental mechanisms governing USNP-inflammatory monocyte interactions, including how the USNP...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of the PPARD/CIITA/MHCII axis in regulating regulatory T cell (Treg) function and its impact on tumor immunity. The $276,450 award to the Salk Institute for Biological Studies will fund experiments to define the molecular mechanisms by which MHCII expression in Tregs is regulated by...
This federal Project Grant award of $509,448.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research to investigate the role of antigen-presenting cells in modulating tumor-specific immune tolerance and metastatic progression. The primary objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development in lymph nodes, and 2) assess therapeutic strategies to...